NCT01809236

Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion

An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Chengdu Kanghong Biotech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study. The study included a fixed treatment period (3 months) and a PRN period (6 months). In the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.

Conditions

• Retinal Vein Occlusion

Interventions

Type	Name	Description
BIOLOGICAL	Conbercept	intravitreal injection of 0.5 mg Conbercept

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-11-01
• Completion: 2014-03-01
• First posted: 2013-03-12
• Last updated: 2014-03-27

Locations

2 sites across 1 country: China